共 247 条
[1]
Spano JP(2005)Impact of EGFR expression on colorectal cancer patient prognosis and survival Ann Oncol 16 102-108
[2]
Lagorce C(2005)Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study Mod Pathol 18 1350-1356
[3]
Atlan D(2017)Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer Cochrane Database Syst Rev 6 337-345
[4]
Milano G(2004)Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 1658-1664
[5]
Domont J(2007)Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 25 569-579
[6]
Benamouzig R(2014)Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study Lancet Oncol. 15 1254-1261
[7]
Shia J(2010)Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer J Clin Oncol 28 1084-1094
[8]
Klimstra DS(2014)Acquired resistance to EGFR-targeted therapies in colorectal cancer Mol Oncol 8 1044-1057
[9]
Li AR(2020)Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: a systematic review and meta-analysis Cancer Med 9 1269-1280
[10]
Qin J(2014)Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution Cancer Discov 4 1757-1765